Navigation Links
MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA
Date:3/26/2012

MOUNTAIN VIEW, Calif., March 26, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX® (dihydroergotamine) inhalation aerosol.

In the Complete Response letter, the FDA requested that the Company address issues relating to chemistry, manufacturing and controls (CMC) and observations from a recent facility inspection of a third party manufacturer. The FDA also indicated that it had not been able to complete review of inhaler usability information requested late in the review cycle by the FDA.  

The FDA did not cite any clinical safety or efficacy issues, nor did the FDA request that any additional clinical studies be conducted prior to approval.  The Company is pleased with the FDA-provided revisions to product labeling and packaging, including correct use of the LEVADEX trade name. The Company continues to pursue approval of LEVADEX for the acute treatment of migraine in adults.

MAP Pharmaceuticals plans to request a meeting with the FDA to discuss the issues raised in the Complete Response letter.

"MAP is committed to making this important new therapy available to people who experience migraine. We will continue to work closely with the FDA to finalize our product labeling and to address the issues raised in the Complete Response letter as quickly as possible," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

Conference Call Information

MAP Pharmaceuticals management will host a conference call on Tuesday, March 27, 2012 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) and individuals may participate in the conference call by dialing (877) 291-1367 (domestic) or  (253) 237-1128 (international). To access the webcast, please visit the Company's website at www.mappharma.com  and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

LEVADEX and TEMPO are trademarks of MAP Pharmaceuticals, Inc.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the regulatory approval process for the Company's LEVADEX product candidate. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, available at http://edgar.sec.gov.

MAP Pharmaceuticals Contact:

Christopher Chai, 650-386-3107 (investors)
Lisa Borland, 650-386-3122 (media)
Denise Powell 510-703-9491 (media)


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
2. Pharmaceuticals: Global Industry Guide
3. Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
4. JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
6. Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
8. Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
9. S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
10. Questcor Pharmaceuticals to Present at the 24th Annual ROTH Conference on March 12, 2012
11. Patented Protection Against Counterfeit Pharmaceuticals and Retail Fraud. ICAP Patent Brokerage Announces for Auction a Patented System for Verification of Purchase and Product Legality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... This analysis is one of the most accurate studies ... date financial data derived from varied research sources to present unique ... the market during the next five years, including a deep dive ...
(Date:3/1/2017)... 2017  Aethlon Medical, Inc. (Nasdaq: AEMD), announced ... European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS ... exosomes have emerged as a significant diagnostic and ... conditions, including cancer, infectious viruses, tuberculosis, Alzheimer,s, and ... is an important addition to Aethlon Medical,s patent ...
(Date:3/1/2017)... DUBLIN , Mar 01, 2017 Research and ... of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to ... Did you ... Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing ... manufacturing base for the production of infectious diseases diagnostics in ...
Breaking Medicine Technology:
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... The Industrial ... March 5, 2017 by raising awareness of the profession of industrial design (ID) and ... robust content geared toward high school students and counselors; parents; and the greater public. ...
(Date:3/1/2017)... BEVERLY HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... invasive cryoablation for the treatment of early stage breast cancer and where it fits ... Screens, Genes & The Choices We Make .” The event brings together leading cancer ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... NYC based ... physical therapy, is pleased to announce the addition of Orthopaedic Surgeon Dr. ... graduated cum laude from Cornell University with a Bachelor of Science degree in biology. ...
(Date:3/1/2017)... ... 2017 , ... “Cleansing Thoughts; Glimpses from My Personal Journal”: ... His voice. “Cleansing Thoughts; Glimpses from My Personal Journal” is the creation of ... and crocheting baby items to donate to the Neonatal Intensive Care Units at ...
(Date:3/1/2017)... ... March 01, 2017 , ... “The Affair is Over Now Go Live ... upheaval of an extramarital affair. “The Affair is Over Now Go Live Your Life ... lay pastor who has dedicated her professional life to teaching and writing about marriage ...
Breaking Medicine News(10 mins):